Synthetic biotinylated peptide compounds derived from Asp-hemolysin: Novel potent inhibitors of platelet-activating factor

Akira Sato, Takeshi Kumagai, Junken Aoki, Keiichi Ebina

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

Platelet-activating factor (PAF: 1-O-alkyl-2-acetyl-sn-glycero-3- phosphocholine), a potent inflammatory mediator, is implicated in many inflammatory diseases and may possibly serve as a direct target for antiinflammatory drugs. We have previously reported that Asp-hemolysin-related synthetic peptides (P4-P29) inhibit the bioactivities of oxidized low-density lipoprotein (ox-LDL) containing PAF-like lipids by direct binding to ox-LDL, which plays a key role in the atherosclerotic inflammatory process. In this study, we investigated whether these peptides inhibit the bioactivities of PAF by binding to PAF and itsmetabolite/ precursor lyso-PAF. In in vitro experiments, P21, one of the peptides, bound to both PAF and lyso-PAF in a dose-dependent manner and markedly inhibited PAF-induced apoptosis in human umbilical vein endothelial cells. Moreover, in in vivo experiments, P4 and P21, particularly their N-terminally biotinylated peptide compounds (BP4 and BP21), inhibited PAF-induced rat paw oedema dose dependently and markedly, and showed sufficient inhibition of the oedema even at doses 150300 times less than the doses of PAF antagonists. These results provide evidence that direct binding of N-terminally biotinylated peptide compounds derived from Asp-hemolysin to PAF and lyso-PAF leads to a dramatic inhibition of the bioactivities of PAF, both in vitro and in vivo, and strongly suggesting that these compounds may be useful as a novel type of antiinflammatory drug for the treatment of several inflammatory diseases caused by PAF.

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalEuropean Journal of Pharmacology
Volume685
Issue number1-3
DOIs
Publication statusPublished - 2012 Jun 15

Keywords

  • Anti-inflammatory drug
  • Biotinylated peptide compound
  • Lyso-PAF
  • PAF
  • PAF inhibitor
  • Platelet-activating factor

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Synthetic biotinylated peptide compounds derived from Asp-hemolysin: Novel potent inhibitors of platelet-activating factor'. Together they form a unique fingerprint.

Cite this